MGC Pharmaceuticals is a drug manufacturers - specialty & generic business based in Australia. MGC Pharmaceuticals shares (MXC) are listed on the Australian Securities Exchange (ASX) and all prices are in Australian dollars. MGC Pharmaceuticals has a trailing 12-month revenue of around $1.3 million. If you're looking to buy shares, check out the steps below.
To buy shares listed in Australia such as MGC Pharmaceuticals, you'll need to sign up to a broker with access to the ASX. Our table can help you compare share trading platforms and choose. Then follow these steps.
Our top pick for
Best for beginner
Our top pick for
Education & learning
Our top pick for
Australian stocks
| 52-week range | $0.3 - $11 |
|---|---|
| 50-day moving average | $0.4162 |
| 200-day moving average | $1.3588 |
| Target price | $20.12 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-3.21 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. However, this is not a recommendation. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Historical closes compared with the last close of A$0.43
| 1 week (2024-04-11) | -1.15% |
|---|---|
| 1 month (2024-03-18) | 2.38% |
| 3 months (2024-01-18) | 4.88% |
| 6 months (2023-10-18) | -71.33% |
| 1 year (2023-04-17) | -95.70% |
|---|---|
| 2 years (2022-04-14) | -98.05% |
| 3 years (2021-04-16) | -99.33% |
| 5 years (2019-04-18) | -99.09% |
| Revenue TTM | $1.3 million |
|---|---|
| Gross profit TTM | $1.3 million |
| Return on assets TTM | -58.96% |
| Return on equity TTM | -307.4% |
| Profit margin | 0% |
| Book value | 0.037 |
| Market capitalisation | $18.4 million |
TTM: trailing 12 months
We're not expecting MGC Pharmaceuticals to pay a dividend over the next 12 months.
MGC Pharmaceuticals's shares were split on a 1:1000 basis on 29 October 2023. So if you had owned 1000 shares the day before the split, the next day you would own 1 share. This wouldn't directly have changed the overall worth of your MGC Pharmaceuticals shares – just the quantity. However, indirectly, the new 99900% higher share price could have impacted the market appetite for MGC Pharmaceuticals shares which in turn could have impacted MGC Pharmaceuticals's share price.
Over the last 12 months, MGC Pharmaceuticals's shares have ranged in value from as little as $0.3 up to $11. A popular way to gauge a stock's volatility is its "beta".
Beta measures a share's volatility in relation to the market. The market (AU average) beta is 1, while MGC Pharmaceuticals's is 1.028. This would suggest that MGC Pharmaceuticals's shares are a little bit more volatile than the average for this exchange and represent, relatively speaking, a slightly higher risk (but potentially also market-beating returns).
MGC Pharmaceuticals Limited provides phytomedicines worldwide. The company produces and supplies medicinal cannabis products; and non-cannabis phytomedicines. Its principal product candidates include CimetrA, which is in phase III clinical trial for the symptomatic treatment of early COVID-19; CannEpil, a phase IIb cannabis-based therapy for drug-resistant Epilepsy; and CogniCann that is in phase II clinical trial for the symptomatic relief of Dementia. In addition, the company provides Irnican that is in preclinical phase for the tetrahydrocannabinol, as well as offers ArtemiC and non-pharma products. Further, it offers consulting services, including clinical research services. MGC Pharmaceuticals Limited was founded in 2014 and is based in Subiaco, Australia.
AMP Ltd Preferred
AUD104.43
ANZ Group Holdings Ltd. Pfd.
AUD101.63
ANZ Group Holdings Ltd. Pfd.
AUD103.41
Challenger Ltd Preferred
AUD105.84
Macquarie Bank Ltd Pref
AUD105.68
Macquarie Group Ltd Pref C
AUD103.11
Macquarie Group Ltd Pref
AUD105.84
Macquarie Group Preferred
AUD102.88
Westpac Banking Corp Pref
AUD102.82
Whitefield Ltd Pref B
AUD98.62
Everything we know about the Tasmea Limited IPO, plus information on how to buy in.
Steps to owning and managing Blinklab shares.
Everything we know about the Maverick Minerals IPO, plus information on how to buy in.
Steps to owning and managing Far Northern Resources shares.
Commodity ETFs can be used to hedge against inflation. Here's what they do, why they should be on your watchlist and how they can help your portfolio.
Looking for the best performing stocks in Australia? We update this list weekly.
Steps to owning and managing Gol Linhas Aéreas Inteligentes SA shares from Australia.
Trade ASX stocks and ETFs with a flat $2 brokerage fee and a low minimum investment of just $10.
These ETFs have the lowest fees on the market, but does that make them the best?
You've heard of CommSec but how does it stack up to the likes of IG, CMC Invest and other players in the market?